CompletedNCT00728195
JNJ-37822681 or placebo for schizophrenia
About this title
Read the official source — NCT00728195This study evaluated the safety and effectiveness of JNJ-37822681 for people with schizophrenia.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of JNJ-37822681 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Burgas and 44 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNovember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 498
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Bulgaria, Estonia, Lithuania, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00728195
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedBurgas, Bulgaria · Pazardzhik, Bulgaria · Radnevo, Bulgaria
43 more locations
- Rousse, Bulgaria
- Sofia, Bulgaria
- Tallinn, Estonia
- Tartu, Estonia
- Kaunas, Lithuania
- Vilnius, Lithuania
- Johor Bahru, Malaysia
- Kuala Lumpur, Malaysia
- Kuching, Malaysia
- Arad, Romania
- Brasov, Romania
- Bucharest, Romania
- Jebel, Romania
- Oradea, Romania
- Sibiu, Romania
- Tg Mures, Romania
- Ekaterinburg Na, Russia
- Moscow, Russia
- Moscow Russia, Russia
- N Novgorod Na, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Tomsk Na, Russia
- Yaroslavl, Russia
- Cape Town, South Africa
- Centurion Gauteng, South Africa
- Pretoria, South Africa
- Gwangju, South Korea
- Gyeongsangnam-Do, South Korea
- Incheon, South Korea
- Seoul, South Korea
- Hualien City, Taiwan
- Kaohsiung City, Taiwan
- Taipei, Taiwan
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kiev, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Russia
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of JNJ-37822681 for people with schizophrenia.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including JNJ-37822681, Olanzapine and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
Long-Term Safety of EVP-6124 Added to Schizophrenia Medication